On July 1, 2026, the U.S. Department of Justice announced non-prosecution agreements totaling $600 million with Alibaba Group and AUS Merchant Services to resolve allegations that the companies failed to prevent merchants from selling illegal pharmaceuticals, controlled substances, listed chemicals, and pill presses through Alibaba.com and AliExpress.com. The resolution represents one of the largest pharmaceutical marketplace enforcement actions ever brought against a Chinese platform and sends a clear message about DOJ's expectations for online marketplaces that serve U.S. consumers.
As part of the resolution, Alibaba admitted that from 2016 to 2024 it failed to prevent approximately 80,000 product sales with a combined merchandise value exceeding $200 million. The scope and duration of the conduct at issue underscore DOJ's willingness to hold platforms accountable for years of inadequate merchant screening, transaction monitoring, and prohibited-product controls. By pursuing both the marketplace operator and its associated payment services provider, DOJ has signaled that enforcement risk extends across the entire ecosystem that enables third-party sales into the United States.
The agreements should be read as a compliance benchmark for any e-commerce operator, payment processor, or platform whose services can be used to reach U.S. consumers. DOJ's theory of liability turns not on whether the platform itself sold prohibited products, but on whether it took reasonable and sustained steps to prevent merchants from doing so. That framing places pressure on marketplaces to demonstrate meaningful onboarding due diligence, ongoing listing surveillance, effective keyword and image-based detection, prompt takedown protocols, and documented escalation procedures for repeat offenders.
Platforms and payment providers should promptly reassess their merchant vetting processes, prohibited-item policies, and monitoring capabilities, with particular attention to controlled substances, listed chemicals, and drug-manufacturing equipment such as pill presses. Boards and senior management should also consider whether existing compliance resources, testing, and internal reporting are commensurate with the volume and risk profile of cross-border third-party sales. Documenting these efforts will be essential to any future engagement with regulators.
This alert is provided for general informational purposes only and does not constitute legal advice. Clients facing questions about marketplace compliance, DOJ enforcement risk, or related regulatory obligations should seek tailored guidance from qualified counsel.